Treatment with deferasirox (Exjade) effectively decreases iron burden in patients with thalassaemia intermedia: results of a pilot study.
Ersi
E
Voskaridou
Eleni
E
Plata
Maroussa
M
Douskou
Manousos
M
Papadakis
Eleni-Evangelia
EE
Delaki
Dimitrios
D
Christoulas
Evangelos
E
Terpos
D000328:Adult; D001565:Benzoates / Q000627:therapeutic use*; D000077588:Deferasirox; D005260:Female; D005293:Ferritins / Q000097:blood; D006321:Heart; D006801:Humans; D007502:Iron Chelating Agents / Q000627:therapeutic use*; D008099:Liver / Q000473:pathology; D008279:Magnetic Resonance Imaging / Q000379:methods; D008297:Male; D008875:Middle Aged; D009206:Myocardium / Q000473:pathology; D010865:Pilot Projects; D011446:Prospective Studies; D016896:Treatment Outcome; D014230:Triazoles / Q000627:therapeutic use*; D017086:beta-Thalassemia / Q000188:drug therapy*
D001565:Benzoates; D007502:Iron Chelating Agents; D014230:Triazoles; D005293:Ferritins; D000077588:Deferasirox